Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.7 USD | +0.27% | +0.54% | -10.14% |
Mar. 19 | Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024 | |
Mar. 19 | Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 3M | Capitalization | 111M |
---|---|---|---|---|---|
Net income 2024 * | -112M | Net income 2025 * | -120M | EV / Sales 2024 * | - |
Net cash position 2024 * | 203M | Net cash position 2025 * | 124M | EV / Sales 2025 * | -4.17 x |
P/E ratio 2024 * |
-1.21
x | P/E ratio 2025 * |
-1.56
x | Employees | 20 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.96% |
Latest transcript on Relmada Therapeutics, Inc.
1 day | +1.37% | ||
1 week | -4.40% | ||
Current month | +1.37% | ||
1 month | -24.39% | ||
3 months | -19.08% | ||
6 months | +23.83% | ||
Current year | -10.87% |
Managers | Title | Age | Since |
---|---|---|---|
Paolo Manfredi
FOU | Founder | 62 | 12-05-30 |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 15-11-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 78 | 15-07-13 | |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 15-11-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.03% | 509 M€ | -.--% | ||
0.00% | 237 M€ | +0.96% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 3.72 | +0.81% | 11 729 |
24-05-01 | 3.69 | +1.37% | 64,008 |
24-04-30 | 3.64 | +3.12% | 147,724 |
24-04-29 | 3.53 | -7.83% | 241,735 |
24-04-26 | 3.83 | +3.51% | 80,013 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.87% | 111M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+4.92% | 22.25B | |
-14.77% | 21.68B | |
-8.70% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- RLMD Stock